Evidence map›Paper›PMID 33625653›Full record

Trial reportInternational journal of clinical pharmacy2021

Evaluation of pharmacists' interventions on drug-related problems and drug costs in patients with cancer pain.

Ping Zhang, Dan Lv, Jin Zhao, Shusen Sun, Ling Li, Yun Liao

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in International journal of clinical pharmacy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Ping ZhangDepartment of Pharmacy, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, 1111 Xianxia Road, Shanghai, 200336, People's Republic of China.
Dan LvDepartment of Pharmacy, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, 1111 Xianxia Road, Shanghai, 200336, People's Republic of China.
Jin ZhaoDepartment of Pharmacy, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, 1111 Xianxia Road, Shanghai, 200336, People's Republic of China.
Shusen SunDepartment of Pharmacy Practice, College of Pharmacy and Health Sciences, Western New England University, 1215 Wilbraham Road, Springfeld, MA, 01119, USA.
Ling LiDepartment of Pharmacy, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, 1111 Xianxia Road, Shanghai, 200336, People's Republic of China.
Yun LiaoDepartment of Pharmacy, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, 1111 Xianxia Road, Shanghai, 200336, People's Republic of China. libra_ly@shsmu.edu.cn.ORCID http://orcid.org/0000-0001-9038-9635
Shanghai Jiao Tong University · CNCentral South University · CN

Funding

School of Medicine, Shanghai Jiao Tong University JDYX2017ZD005
6 · The paper itself

Abstract

backgroundDrug-related problems (DRPs) prevent patients from fully benefiting from drug treatment. Unrelieved pain in patients with cancer is still widespread. Pharmacists can play a role in closely monitoring cancer patients, pain control maintenance, and patient consultation.

objectiveTo evaluate the clinical effects and changes in drug costs of pharmacists' interventions on patients with DRPs related to cancer pain.

settingAn academic teaching hospital in Shanghai, China.

methodsPatients with cancer pain admitted to Shanghai Tongren Hospital from October 2018 to February 2019 were randomized into the intervention and control groups. The Pharmaceutical Care Network Europe classification V8.02 was used to categorize DRPs treated with analgesics. Patients' pain relief, the occurrence of adverse drug reactions, and drug cost-saving through the resolution of DRPs were evaluated.

main outcome measureProblems and causes of drug-related problems, interventions proposed, and outcome of pharmacy recommendations.

resultsA total of 172 patients were enrolled and randomized into the intervention group (n = 86) and the control group (n = 86). The pharmacist detected 66 DRPs in 48 patients (55.8%) of the intervention group, an average of 0.8 DRPs per patient. A total of 149 interventions were proposed by the pharmacist. Compared to the control group, the drug intervention produced more pain relief on the third day of analgesic treatment. In the intervention group, a total of 33 DRP interventions resulted in cost changes, saving a drug cost of $489.90, averaging $11.94 per intervention.

conclusionOur study suggests that pharmacy service in patients with cancer pain can resolve drug-related problems and reduce drug costs.

Indexed as

Cancer PainDrug-Related Side Effects and Adverse ReactionsNeoplasmsPharmaceutical PreparationsPharmacy Service, HospitalChinaDrug CostsHumansPharmacistsPharmaceutical PreparationsCancer painChinaPCNE classificationPharmaceutical carePharmacistsPharmacy intervention

Identifiers

PMID33625653
OpenAlexW3129215785

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.